Social media boosting patient recruitment, but FDA guidance needed

By Gareth Macdonald

- Last updated on GMT

CRO and Pharma patient recruitment efforts can benefit from social networks and online patient groups, but clarification from the US FDA is still needed. spoke with Brian Loew, CEO of Inspire, an online community of over 70 disease-specific patient communities, who explained that the benefits go beyond access to patients.

“It’s not just access to large number of patients, it’s the fact that those patients are deciding in large number to participate in clinical trials.”

Loew went on to explain that this volunteering process helps contract research organisations and pharmas tackle some of the prescreening, selection and permission hurdles that can otherwise hamper recruitment.

However, he added, CROs still face regulatory hurdles when accessing these types of social networks that would benefit from further clarification from regulators.

The FDA could help us all by being clear about what is ok and what is not ok…and the absence of that clarity is making it difficult for industry​.”

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers